We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies. Close

Product Liability

Liability Risk and Insurance

Product Liability

FDA warning letter for US breast implant manufacturers

The US Food and Drug Administration (FDA) has issued warning letters to two breast implant manufacturers for failure to comply with various regulatory requirements. The letter to California-based Allergan was for failing to comply with requirements, under two separate pre-market approval orders, to conduct post-approval studies to assess the long-term safety and risks of two models of breast implants, both of which were voluntarily recalled from the market last year.

The rest of this document is only available to i-law.com online subscribers.

If you are already a subscriber, please enter your details below to log in.

Enter your email address to log in as a user on your corporate account.
Remember me on this computer

Not yet an i-law subscriber?


Request a trial Find out more